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a-Factor, a 13-amino-acid pheromone secreted by haploid a cells of Saccharomyces cerevisiae, binds to Ste2p,
a seven-transmembrane, G-protein-coupled receptor present on haploid a cells, to activate a signal transduc-
tion pathway required for conjugation and mating. To determine the structural requirements for a-factor
activity, we developed a genetic screen to identify from random and semirandom libraries novel peptides that
function as agonists or antagonists of Ste2p. The selection scheme was based on autocrine strains constructed
to secrete random peptides and respond by growth to those that were either agonists or antagonists of Ste2p.
Analysis of a number of peptides obtained by this selection procedure indicates that Trp1, Trp3, Pro8, and Gly9
are important for agonist activity specifically. His2, Leu4, Leu6, Pro10, a hydrophobic residue 12, and an
aromatic residue 13 are important for both agonist and antagonist activity. Our results also show that
activation of Ste2p can be achieved with novel, unanticipated combinations of amino acids. Finally, the results
suggest the utility of this selection scheme for identifying novel ligands for mammalian G-protein-coupled
receptors heterologously expressed in S. cerevisiae.
Haploid Saccharomyces cells of mating type a secrete a
13-amino-acid pheromone, a-factor (Trp1-His2-Trp3-Leu4-
Gln5-Leu6-Lys7-Pro8-Gly9-Gln10-Pro11-Met12-Tyr13), that
can bind and stimulate Ste2p, a G-protein-coupled receptor
expressed on the surface of haploid cells of mating type a
(reviewed in reference 26). Binding of a-factor to Ste2p acti-
vates the pheromone signaling pathway by promoting on the
cytoplasmic side of the plasma membrane dissociation of a
coupled heterotrimeric G protein into its constituent a subunit
and bg complex. The bg complex in conjunction with Cdc42p
initiates a kinase cascade that results in activation of mitogen-
activated protein kinase homologs, Kss1p and Fus3p (reviewed
in reference 17). These activated kinases promote both cell
cycle arrest, through inactivation of the cyclin B/p34cdc28 com-
plex in a process mediated by Far1p, and transcription of a
variety of genes required for mating and conjugation, mediated
by the Ste12p transcriptional activator. Activation of this signal
transduction pathway is essential for productive mating, and
mutations that attenuate this pathway result in sterility.
Current knowledge of a-factor suggests a complex structure-
function relationship. Although determinants of its various
biological activities are not restricted to discrete peptide re-
gions, the determinants may be more heavily concentrated in
certain domains. For example, residues that initiate signaling
may be concentrated in the N terminus, while those that me-
diate binding may dominate the C-terminal region. This sug-
gestion is based on observations that removal or substitution of
Trp1, His2, or Trp3 results in loss of biological activity that
exceeds the relatively small reductions in binding affinity (10,
22). For example, removal of Trp1 to form des-Trp1-a-factor
yields a peptide with about 10% the affinity but less than 1%
the bioactivity of a-factor. Further mutation of this truncated
peptide to des-Trp1-[Phe3]-a-factor or des-Trp1-[Ala3]-a-fac-
tor causes complete loss of bioactivity with no further diminu-
tion of affinity (22). A relatively minor role for the N-terminal
region in binding compared with agonist efficacy is further
indicated by the observation that removal of both Trp1 and
His2 produces an analog that shows about 25% the binding
affinity but less than 0.1% the bioactivity of a-factor (10, 22). In
contrast, coincident removal of the C-terminal Met12 and
Tyr13 leads to complete loss of agonist activity that is ac-
counted for by loss of affinity for Ste2p (10). While such data
support a model of a-factor in which the N and C termini are
largely devoted to agonist efficacy and binding, respectively,
additional data indicate that such a model is a crude approx-
imation. Thus, it has been observed that deletion of Tyr13
alone yields a peptide that acts synergistically with a-factor
(10). Also, the middle region of a-factor is critical for biolog-
ical activity, perhaps as a result of the formation of a transient
type II b turn (12, 14, 30).
We have further explored the structure-function relation-
ship of a-factor by using a genetic system to select a-factor
analogs that act as either agonists or antagonists of Ste2p. Our
results identify novel peptide agonists and antagonists of Ste2p
whose sequences provide information for the developing
model of a-factor structure and activity. The genetic selection
strategy may be used to discover novel ligands for any G-
protein-coupled receptor functionally expressed in Saccharo-
myces cerevisiae.
MATERIALS AND METHODS
Strains. S. cerevisiae CY1455 (MATa bar1::hisG far1-1 fus1-HIS3 ste14::TRP1
ura3 trp1 leu2 his3) and CY1892 (MATa bar1::hisG fus1-HIS3 ura3 trp1 leu2 his3
SUC1) were obtained by standard genetic techniques, with IH2512 (provided by
I. Herskowitz), SY1390 (27) (provided by G. Sprague), SM1188 (24) (provided
by S. Michaelis), and JY512 (provided by J. Trueheart) serving as the original
sources of the far1-1, fus1-HIS3, ste14, and bar1 alleles, respectively. CY2797
(MATa tbt1-1 bar1::hisG far1-1 fus1-HIS3 ste14::TRP1 ste2D1154 ura3 trp1 leu2
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his3) was obtained from CY1455 by the two-step disruption (4) of STE2 with
plasmid CP1154, constructed as follows. A 4.3-kb BamHI fragment containing
STE2 was isolated from YEp24-STE2 (provided by J. Thorner) and subcloned
into pALTER (Promega) for insertion of SpeI sites 7 nucleotides upstream of the
start codon and 9 nucleotides downstream of the stop codon. The mutagenized
BamHI fragment was subcloned into the BamHI site of YIp19, and the resulting
plasmid was cut with SpeI and religated to yield CP1154.
Media. Media were prepared essentially as described previously (25). SC-Ura
and SC-His are yeast nitrogen base containing 2% glucose and an amino acid and
adenine supplement (0.5 g/liter) lacking uracil and histidine, respectively; SC-
UraHis lacks histidine as well as uracil. 3(1,2,4)-Aminotriazole (Sigma, St. Louis,
Mo.) was added as indicated to titrate the activity of the HIS3 reporter enzyme
(15).
Vector construction. The vector used for peptide expression by yeast strains
was constructed as follows. A fragment comprising approximately 600 bp of the
upstream activation sequence of the ADH1 promoter (210 to about 2600
relative to the translational start) was obtained from pAAH5 (1) and cloned as
an SphI-to-HindIII fragment into the BamHI and HindIII sites in the polylinker
of pRS426 (8). A fragment that contains 5 bp of the MFa1 mRNA leader
followed by sequence encoding a modified prepro segment of the a-factor pre-
cursor was then cloned into the HindIII site such that expression of sequences
fused to the MFa1 prepro leader is directed by the ADH1 promoter (Fig. 1). The
prepro-encoding segment is modified as a result of mutation of TA (nucleotides
247 and 248 relative to the start of the MFa1 coding sequence) to CT, thereby
introducing an AflII site for possible insertion of oligonucleotides while mutating
Asp83 to Leu. Processing of the a-factor precursor is tolerant to mutations at this
residue (7). The prepro sequences terminate in aHindIII site, as they do in native
MFa1 and MFa2, followed by a 1-kb stuffer fragment encoding the a fragment
of lacZ joined via a BglII site at its 39 end to approximately 300 bases of theMFa1
39 untranslated sequence. The stuffer fragment facilitates library construction by
allowing more complete isolation of HindIII- and BglII-cut vector from singly cut
vector. At the same time, vector background in the libraries can be determined
from the relative numbers of blue and white bacterial colonies following trans-
formation with the plasmid libraries.
Construction of libraries. Three chemically synthesized, partially random oli-
gonucleotide libraries were constructed to determine structural features of the
N-terminal, middle, and C-terminal regions of a-factor that contribute to its
bioactivity. The N-terminal (Nterm) library was made with oligonucleotides that
use triplets NNK to encode residues 2, 3, and 4 of the mature peptide (N is any
nucleotide and K is either G or T), triplets TNK to encode the first residue while
preserving the HindIII site, and codons 5 through 13 of genuine a-factor. Thus,
this library encodes amino acids C, F, L, S, W, and Y at residue 1 of the peptide,
any amino acid at residues 2, 3, and 4, and the normal a-factor residues at the
remaining nine positions (viz., QLKPGQPMY). The double-stranded oligonu-
cleotides containing the random nucleotides were constructed as follows. First, 1
nmol each of the two single-stranded oligonucleotides 59-GCCGTCAGTAAA
GCTTNKNNKNNKNNKCAGCTAAAACCTGGCCAGCCTATGTACTGAT
CAGTCTGTGACGC-39 and 59-GCGTCACAGACTGATCA-39 (N is an
equimolar mixture of A, C, G, and T, and K is equimolar G and T) were
annealed by combining in 200 ml of 40 mM Tris-HCl (pH 7.5), 10 mMMgCl2, 0.1
mg of bovine serum albumin per ml, and 0.5 mM dithiothreitol, heating the
mixture to 658C for 20 min, and then slowly cooling it to 378C. The partially
double-stranded oligonucleotides were then filled in by adding 5 ml of 10 mM
deoxynucleoside triphosphates and 3 ml of Sequenase (13 U/ml; United States
Biochemical Corp.) followed by successive incubations at 378C for 30 min and
658C for 20 min. The DNA was then cut with HindIII and MboI, the digested
DNA was gel isolated, and approximately 5 pmol was ligated to 1.5 pmol of
HindIII- and BglII-cut expression vector (Fig. 1) in 1 ml at 168C overnight. The
MboI-BglII junction creates a stop codon immediately after the triplet encoding
residue 13. Transformation of Escherichia coli JS5 with the ligation mixture
yielded about 108 ampicillin-resistant clones that should contain practically all of
the 6 3 105 possible nucleotide sequences. Three of the possible nucleotide
sequences should encode authentic a-factor, which itself is one of about 6.4 3
104 possible peptides encoded by the library. The quality of the library was
evaluated by sequencing the peptide-encoding inserts in plasmids recovered from
20 randomly chosen yeast clones that had been transformed with the E. coli-
amplified library. All 20 inserts encode tridecapeptides, and the frequencies of
amino acids at the randomized positions were not significantly different from
those predicted by chance alone.
The Mid5 library was made with oligonucleotides that use triplets NNK in the
region encoding amino acids 5 through 9; other triplets encode a-factor amino
acids. The double-stranded oligonucleotides were constructed as described for
the Nterm library, but with the following single-stranded oligonucleotides: 59-G
CCGTCAGTAAAGCTTGGCATTGGTTGNNKNNKNNKNNKNNKCAGCC
TATGTACTGATCAGTCTGTGACGC-39 and 59-GCGTCACAGACTGATC
A-39. As with the Nterm library, the oligonucleotides used to construct the Mid5
library were digested with HindIII and MboI and cloned into the HindIII- and
BglII-cut expression vector (Fig. 1). The theoretical complexity of this library is
3.4 3 107 different nucleotide sequences encoding 3.2 3 106 different peptides.
Transformation of E. coli JS5 yielded about 107 ampicillin-resistant clones, which
should contain about 25% of the possible nucleotide sequences, encoding about
95% of the 3.2 3 106 possible tridecapeptides. All 20 randomly chosen yeast
colonies transformed with the E. coli-amplified library were found to carry
plasmids that encode tridecapeptides of the expected semirandom sequences,
and the frequencies of amino acids at the randomized positions are not signifi-
cantly different from that predicted by chance alone.
The Cterm library encodes a-factor amino acids at residues 1 through 9 and
random, NNK-encoded amino acids at residues 10 through 13. As with the
Nterm and Mid5 libraries, the double-stranded oligonucleotides constructed
from two single-stranded oligonucleotides (in this case 59-GCCGTCAGTAAA
GCTTGGCATTGGTTGCAGCTAAAACCTGGCNNKNNKNNKNNKTGAT
CAGTCTGTGACGC-39 and 59-GCGTCACAGACTGATCA-39) were digested
with HindIII and MboI and cloned into HindIII- and BglII-cut expression vector
(Fig. 1). Transformation of E. coli JS5 yielded about 4 3 108 ampicillin-resistant
clones. Sequencing of plasmids isolated from randomly chosen yeast transfor-
mants, however, indicated that the quality of the library was low. Specifically,
none of 30 plasmids isolated from unselected yeast encode tridecapeptides with
the expected semirandom structure. Rather, most of these plasmids carry frame-
shift mutations within the first four codons of the inserts; others show substitu-
tion of several N-terminal codons; and one contains a 6-bp substitution of the
expected Leu4 codon. As a result, the diversity of this library is greater than
intended, and the chance that any particular peptide-encoding sequence is
among the yeast transformants is lower than intended.
Transformation protocols. Following ligation of double-stranded oligonucle-
otides and the vector, the 1-ml ligation reaction mixture was extracted with
phenol and chloroform, ethanol precipitated, and resuspended in 100 ml of
water. Fifty microliters of the ligated DNA was then added to 200 ml of electro-
competent E. coli JS5, and 60 ml was aliquoted to four cuvettes for electropo-
ration at 1.8 kV, 25 mF, and 200 V. The bacteria were then combined in 5 ml of
LB supplemented with 20 mM glucose and incubated at 378C for 1 h, and
aliquots were removed to estimate library size; the remaining bacteria were
added to 500 ml of LB with ampicillin for overnight growth at 378C for isolation
of library DNA. Yeast cells were transformed with the library DNA by electro-
poration as described by Becker and Guarente (2), using 1 to 25 mg of library
DNA and approximately 108 cells per 100 ml of transformation mixture.
Chemically synthesized peptides. Peptides were synthesized and prepared to
50 to 70% purity by Macromolecular Resources (Colorado State University, Fort
Collins). Peptides were dissolved in dimethyl sulfoxide to 10 mg/ml, and dilutions
were made in water to 0.5 mg/ml.
Secondary assays for agonist and antagonist activities. (i) Liquid growth
assay. Potential autocrine strains, grown overnight in SC-Ura, were washed in
water and resuspended in SC-His to an optical density at 600 of 0.012 (ca.
120,000 cells per ml). Samples of 90 ml were aliquoted to the wells of a 96-well
plate that contain 10 ml of the same medium but with sufficient aminotriazole to
give a final concentration 0.2 mM. The optical density at 600 nm was measured
after 15 h at 308C and compared with that of a strain of CY1455 that had been
transformed with empty peptide vector, CP1625 (negative control), and with an
a-factor-expressing plasmid, CP1219 (positive control). The reading of the neg-
ative control was subtracted from those of the experimental strain and positive
FIG. 1. Design of cassette for expression of a-factor and the semirandom
a-factor libraries. Expression of a-factor or the semirandom libraries in the
context of the a-factor prepro sequence is accomplished by cloning the peptide-
encoding oligonucleotides, containing HindIII and either BclI orMboI ends, into
HindIII- and BglII-digested vector, thereby replacing a lacZ-containing fragment
in the vector with the oligonucleotides. The BclI-BglII and MboI-BglII junctions
encode an in-frame stop codon following the 13th codon of each oligonucleotide.
Processing by Kex2p and Ste13p of the primary translation products encoded by
the resulting plasmids is predicted to generate tridecapeptides identical to a-fac-
tor over the entire length (a-factor), the C-terminal nine amino acids (Nterm
library), the N- and C-terminal four amino acids (Mid5 library), or the N-
terminal nine amino acids (Cterm library).
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control, and the growth of the experimental strain is expressed as the ratio of its
corrected growth to that of the positive control. Only those strains that exhibit
positive growth ratios are considered to express Ste2p agonists.
(ii) Paracrine arrest assay. A suspension of strain CY1455 carrying agonist-
encoding plasmids (ca. 10 ml containing 107 cells) was spotted onto a YPD plate
containing a lawn of strain CY1892, which undergoes growth arrest upon stim-
ulation of Ste2p. In this halo assay, a-factor-like activity of peptides released by
the spotted cells is observed as a clear zone of growth-arrested CY1892 sur-
rounding the spotted cells.
(iii) Paracrine activation assay. A suspension of strain CY1455 carrying ago-
nist-encoding plasmids (ca. 10 ml containing 107 cells) was spotted onto an
SC-His plate containing 0.2 mM aminotriazole and prespread with a lawn of
strain CY1455, which grows on this medium upon stimulation of Ste2p. a-Factor-
like activity of peptides released by the spotted cells is observed as a corona of
growth surrounding the spotted cells.
Statistical analyses. We make the assumption that if there is no selection for
a particular residue at a given position of a recovered peptide, the frequency of
appearance of that residue at that position will be described by the binomial
distribution. Accordingly, if genetic selection is operative, the frequency of ap-
pearance of the residue at that position will differ from the frequency predicted
by the binomial distribution. This assumption allows standard statistical analyses
to be used to determine if the observed frequency may be due to chance alone.
We attempted to assess the reasonableness of this assumption by (i) sequencing
plasmids derived from Ura1 yeast clones that had been transformed with the
library but not selected for growth on selective medium (i.e., medium containing
a-factor or lacking histidine); (ii) tabulating the observed frequencies of encoded
amino acids; and (iii) comparing these observed frequencies with the frequencies
predicted by the oligonucleotide synthesis strategy used to construct the libraries.
In this case, where no genetic selection is operative, the observed frequencies
were not different from that predicted by the binomial distribution to be due to
chance alone. This test of the appropriateness of the binomial distribution for
our purposes is not particularly discriminating, and so the distribution must be
regarded as an approximate description of random events in our system. But
results that deviate significantly from predictions of the distribution nonetheless
indicate the existence of nonrandom influences. We assume that these deviations
result from the genetic selections that we impose on the system. Specifically, we
base the predictions of the binomial distribution on the oligonucleotide synthesis
strategy. We infer the existence of selection for or against a particular amino acid
or class of amino acids at a particular position if the probability that the observed
frequency can be described by the binomial distribution is less than 1024. Such
an apparently conservative requirement for significance is appropriate given the
large number of comparisons made (typically 20 at each of the 13 positions).
For purposes of data analysis, the amino acids A, C, F, G, H, I, K, L, M, T, V,
W, and Y are hydrophobic, and F, H, W, and Y are aromatic (29).
RESULTS
Identification of Ste2p agonists. We have developed a pro-
tocol for identifying possible peptide agonists of the Ste2p
receptor. For the discovery of Ste2p agonists, we used strain
CY1455, which is engineered to grow under conditions of his-
tidine starvation only if it synthesizes and secretes a Ste2p
agonist. CY1455 contains HIS3 coding sequences under the
control of the genomic FUS1 promoter, so that His3p expres-
sion is induced upon activation of the pheromone signaling
pathway. In addition, this strain carries a far1 mutation to
prevent growth arrest consequent to activation of the phero-
mone response pathway, a bar1 mutation to reduce degrada-
tion of a-factor and other similar peptides, and a ste14 muta-
tion to reduce background signaling through the pheromone
response pathway.
The protocol for identification of Ste2p agonists is schema-
tized in Fig. 2. CY1455 (2 3 108 cells) was transformed with 1
mg of each of the plasmid libraries described in Materials and
Methods and plated onto uracil-deficient solid medium to se-
lect for transformants. Following 3 days of growth at 308C, the
transformants were replica plated en masse to histidine-defi-
cient medium containing 0.2 or 0.5 mM aminotriazole, a com-
petitive inhibitor of the HIS3 gene product (16, 28). These
concentrations of aminotriazole are sufficient to eliminate the
growth of unstimulated CY1455 that results from basal activity
of the FUS1 promoter. Transformants secreting peptides with
agonist activity toward Ste2p were identified as growing colo-
nies, due to autocrine activation of cells expressing a-factor-
like peptides, surrounded by a corona of growth, due to para-
crine activation of cells that do not themselves encode agonist
peptides. An example of this pattern is shown in Fig. 3. Auto-
crine cells were colony purified by streaking onto uracil-defi-
cient medium and retested for histidine prototrophy in the
presence of 0.2 mM aminotriazole. Plasmids were isolated
from the autocrine cells, amplified in E. coli, and reintroduced
into the CY1455 test strain. The resulting transformants were
tested for histidine prototrophy, and plasmids that enabled
growth on histidine-deficient solid medium were introduced
into CY2797, a derivative of CY1455 in which STE2 was dis-
rupted, to confirm dependence on Ste2p.
Strains of CY1455 bearing plasmids that exhibited Ste2p
agonist activity were further tested in three additional assays.
In the first assay (liquid growth assay), suspensions of the
strains were tested for growth in liquid media lacking histidine
and containing aminotriazole concentrations of 0 and 0.2 mM.
In the second assay (paracrine arrest assay), the Ste2p agonist
activities of the plasmid-encoded peptides were tested for abil-
ity to arrest the growth of a supersensitive strain; specifically,
agonist-secreting cells were spotted onto an overlay of tester
cells that undergo growth arrest in the presence of a-factor. In
the third assay (paracrine activation assay), agonist-secreting
cells were spotted onto histidine-deficient medium on which a
background lawn of CY1455 had been spread; peptides that
are released by the agonist-secreting cells can stimulate the
FIG. 2. Protocol for genetic selection of Ste2p agonists. Tests that are boxed
in the diagram represent criteria that must be satisfied by candidate agonists.
FIG. 3. Autocrine selection of peptide agonists of the Ste2p receptor. Clones
secreting a-factor-like peptides were distinguished from constitutively activated
mutant clones by a corona of growing cells that show paracrine response to
secreted peptides.
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background lawn, resulting in a corona of satellite colonies
surrounding the spotted cells. Note that the first assay is an
autocrine assay, while the second and third are paracrine as-
says. These paracrine assays reflect not only the agonist activity
of a secreted peptide but also factors such as the permeability
of the cell wall to the peptide and the diffusivity of the peptide
in the solid agar-based media. The results of these assays are
presented below.
Identification of Ste2p antagonists. The protocol for isola-
tion of Ste2p antagonists is outlined in Fig. 4. Strain CY1892
carries the a-factor receptor coupled to the normal growth
inhibition response, so that cells plated on medium containing
25 nM a-factor fail to grow. We anticipated that any cell
producing a peptide that functioned as a Ste2p antagonist
would interdict the growth arrest signal elicited by a-factor and
allow the cell to grow. Accordingly, CY1892 (3.5 3 108 cells)
was transformed with 25 mg of the libraries described in Ma-
terials and Methods. Transformants were selected on medium
lacking uracil and replica plated to medium lacking uracil but
containing 25 nM a-factor. a-Factor-resistant colonies were
isolated, colony purified, and assessed for the plasmid depen-
dence of the a-factor resistance. Specifically, a-factor-resistant
transformants were cured of episome and retested for sensi-
tivity to a-factor. In addition, plasmids from each possible
antagonist-producing strain were amplified in E. coli and rein-
troduced into naive CY1892, and the transformants tested for
resistance to growth arrest by a-factor. Finally, the agonist
activity of the putative antagonist was determined by trans-
forming CY1455 with plasmids encoding candidate antagonists
and measuring the growth of the peptide-secreting strain on
histidine-deficient medium containing 0.2 mM aminotriazole.
Antagonist-encoding plasmids that fail to confer autocrine his-
tidine prototrophy are referred to as pure antagonists; those
that confer detectable growth on histidine-deficient media are
designated partial agonists.
Ste2p agonists and antagonists isolated from the Nterm
library. Transformation of strain CY1455 with the Nterm li-
brary yielded 9 3 105 Ura1 transformants, so that each pep-
tide, including a-factor, should have been represented in yeast
14 times on average. Transformation of strain CY1892 gave
2 3 106 Ura1 transformants, leading to the expectation that
each peptide would have been represented about 30 times
among these transformants. However, multiple isolations of
the same peptide from the Nterm library were rare, even when
all of the Ura1 transformants were examined, suggesting that
the reliability of the selection procedure in detecting the pep-
tide-dependent phenotype is less than 100% and/or that plas-
mids encoding particular peptides are unevenly represented.
Indeed, reconstruction experiments indicated that only 20% of
cells containing an a-factor-encoding plasmid were recovered
by the genetic screen for Ste2p agonists when present at a
frequency of 1 a-factor-secreting cell in 105. We expect that
cells expressing peptides with weaker phenotypes would have
been recovered at even lower frequencies, reflecting a bias of
the selection system toward recovery of more potent agonists.
The Nterm library can encode amino acids C, F, L, S, W, and
Y at residue 1 of the peptide, any amino acid at residues 2, 3,
and 4, and the normal a-factor residues at the remaining 9
positions (viz., QLKPGQPMY). Genetic selection for Ste2p
agonists identified 11 plasmids that confer Ste2p-dependent,
autocrine histidine prototrophy, indicating that they encode
peptides with a-factor-like activity (Table 1). Six of the 11
plasmids encode genuine a-factor, while the other five plas-
mids encode four novel a-factor analogs. The six plasmids
encoding a-factor are presumably independent isolates, since
the three possible a-factor-coding sequences are each repre-
sented one, two, and three times. Considering the peptides
encoded by the 11 isolates, statistical analysis indicates signif-
icant bias for tryptophan, histidine, tryptophan, and leucine at
positions 1, 2, 3, and 4, respectively.
Histidine prototrophy of the agonist-secreting strains was
tested in histidine-deficient liquid culture containing 0 and 0.2
mM aminotriazole. (We have observed that an aminotriazole
concentration of 0.2 mM in liquid media is roughly equivalent
to 1 mM in solid media.) All strains exhibit greater growth than
a strain carrying the empty expression vector, confirming that
the strains synthesize peptides with a-factor-like activity (Table
1). However, in the absence of knowledge of the peptide con-
centrations to which Ste2p is exposed, these data provide no
indication of the relative potencies of the secreted peptides.
Also listed in Table 1 is a paracrine measure of agonist activity:
the width of the zone of growth arrest of a lawn of strain
CY1892 on which 107 agonist-secreting cells were spotted (Fig.
5). Note that strains that exhibited equivalent growth rates in
liquid media can give very different paracrine measures of
agonist activity. Such apparent discrepancies between auto-
crine and paracrine assays of agonist activity may reflect dif-
ferences in diffusion of the peptides in solid agar or in their cell
wall permeabilities. The discrepancies may also reflect differ-
ent thresholds for an agonist effect in the two assays.
Genetic selection for antagonists using the same Nterm li-
brary yielded many more positive clones than selection for
agonists. From approximately 140 Ura1 transformants of
strain CY1892 that exhibited a-factor resistance, 38 were cho-
sen for detailed analysis. Twenty-three of these transformants
were shown to exhibit reproducible a-factor resistance that was
plasmid dependent. These yielded 18 unique peptides encoded
by 20 different plasmids, indicating that the frequency of de-
tection of antagonist-secreting clones was less than 100%. Of
the 20 plasmids with unique nucleotide sequences, 10 encoded
peptides that display some agonist activity (see Table 3), as
measured by aminotriazole-resistant growth on solid media.
That is, 10 different plasmids were identified in the selection
for antagonists that confer histidine prototrophy when trans-
formed into strain CY1455. The remaining 10 unique plasmids,
encoding nine different peptides, fail to confer histidine prot-
otrophy on strain CY1455 and are therefore considered to
encode pure antagonists (Table 2).
The predicted sequences of the pure antagonists collectively
exhibit a strong preference for histidine in position 2 and for
leucine in position 4. Similar preferences were observed for
agonists isolated from this same library. No significant bias is
FIG. 4. Protocol for genetic selection of Ste2p antagonists. Tests that are
boxed in the diagram represent criteria that must be satisfied by candidate
antagonists.
VOL. 16, 1996 STRUCTURE-FUNCTION ANALYSIS OF a-FACTOR 4703
evident for any amino acid at position 1, and four of the six
possible amino acids are found at this position among the nine
antagonists. Similarly, no bias for any particular amino acid at
position 3 is evident among the antagonists.
Ste2p agonists and antagonists isolated from the Mid5 li-
brary. The Mid5 library encodes the a-factor amino acids W,
H, W, and L at positions 1, 2, 3, and 4, respectively, and Q, P,
M, and Y at residues 10, 11, 12, and 13, respectively. Residues
5 through 9 are unconstrained. Transformation of strain
CY1455 with 1 mg of the library yielded 3 3 105 Ura1 trans-
formants, so that the chance that a particular peptide would
have been represented by the CY1455 Ura1 transformants was
less than 10%. Genetic selection for Ste2p agonists yielded 16
plasmids that encode tridecapeptides with agonist activity (Ta-
ble 1); the nucleotide sequences of 2 of these 16 plasmids was
identical, suggesting that they were not independent isolates.
Statistical analysis indicates the following preferences among
the 15 unique predicted peptides. At residue 5 or 7, there is no
significant preference for any amino acid. Position 6 shows a
strong preference for leucine, with all 15 isolates having a
leucine at this position. Position 8 is biased toward proline and
alanine. Finally, position 9 shows an apparently absolute pref-
erence for glycine. Collectively, the results demonstrate selec-
tive pressure for Ste2p agonists to contain a leucine at residue
6, a glycine at position 9, and either a proline or an alanine at
position 8. While a-factor conforms to these structural require-
ments, the apparent ability of alanine to substitute for proline
at position 8 is noteworthy in light of the observations of
Becker et al. that a-factor forms a type II b turn at Pro8-Gly9
(12–14).
FIG. 5. Paracrine arrest assay. Each panel shows a halo of growth-arrested
CY1892 cells surrounding CY1455 cells transformed with a plasmid that ex-
presses genuine a-factor or a Ste2p agonist isolated from the Mid5 library. The
peptide predicted to be secreted is indicated on each panel, where S5S7 indicates
[Ser5,Ser7]-a-factor, S5D7A8 indicates [Ser5,Asp7,Ala8]-a-factor, etc. Cells
transformed with empty vector fail to produce a halo. The widths of the zones of
growth arrest due to these and all other Ste2p agonists found in this study are
expressed relative to a-factor in Table 1.
TABLE 1. Genetically selected Ste2p agonists
Library Predicted amino acid sequencea Autocrine growthactivityb,c
Paracrine growth
arrest activityc,d
Nterm Ser Val Leu Cys Gln Leu Lys Pro Gly Gln Pro Met Tyr 20 0
Trp Gln Trp Leu Gln Leu Lys Pro Gly Gln Pro Met Tyr 100 10
Trp Gln Trp Leu Gln Leu Lys Pro Gly Gln Pro Met Tyr 100 10
Trp His Trp Leu Gln Leu Lys Pro Gly Gln Pro Met Tyr 100 100
Trp His Trp Leu Gln Leu Lys Pro Gly Gln Pro Met Tyr 100 100
Trp His Trp Leu Gln Leu Lys Pro Gly Gln Pro Met Tyr 100 70
Trp Ser Trp Leu Gln Leu Lys Pro Gly Gln Pro Met Tyr 90 0
Trp Tyr Trp Leu Gln Leu Lys Pro Gly Gln Pro Met Tyr 90 0
Mid5 Trp His Trp Leu Arg Leu Gln Pro Gly Gln Pro Met Tyr 90 70
Trp His Trp Leu Arg Leu Gln Ser Gly Gln Pro Met Tyr 90 70
Trp His Trp Leu Arg Leu Gly Ala Gly Gln Pro Met Tyr 120 80
Trp His Trp Leu Arg Leu Ser Ala Gly Gln Pro Met Tyr 100 70
Trp His Trp Leu Cys Leu Asp Ala Gly Gln Pro Met Tyr 80 0
Trp His Trp Leu Gln Leu Ser Ala Gly Gln Pro Met Tyr 90 50
Trp His Trp Leu Leu Leu Arg Pro Gly Gln Pro Met Tyr 80 50
Trp His Trp Leu Ser Leu Asp Ala Gly Gln Pro Met Tyr 70 20
Trp His Trp Leu Ser Leu Arg Ala Gly Gln Pro Met Tyr 70 50
Trp His Trp Leu Ser Leu Gly Ala Gly Gln Pro Met Tyr 90 50
Trp His Trp Leu Ser Leu Ser Pro Gly Gln Pro Met Tyr 90 80
Trp His Trp Leu Ser Leu Tyr Pro Gly Gln Pro Met Tyr 80 50
Trp His Trp Leu Ser Leu Val Pro Gly Gln Pro Met Tyr 80 50
Trp His Trp Leu Thr Leu Met Ala Gly Gln Pro Met Tyr 80 60
Trp His Trp Leu Tyr Leu Arg Pro Gly Gln Pro Met Tyr 90 60
Cterm Trp His Trp Leu Gln Leu Thr Pro Gly Gln Pro Met Tyr 100 100
a Peptide sequences are predicted to be encoded by plasmids isolated from the Nterm, Mid5, and Cterm libraries by genetic selection for Ste2p agonists. Amino acids
encoded by intentionally variable codons are shown in boldface. Each peptide is encoded by at least one unique nucleotide sequence.
b Growth activity in SC-His of CY1455 transformed with peptide-encoding plasmid as a percentage of growth of CY1455 transformed with a-factor-encoding plasmid.
c Values shown are from single experiments in which all strains were simultaneously tested and are rounded to the nearest multiple of 10%. Values obtained on
retesting of particular strains were within 20 and 25%, respectively, of the values shown for the autocrine growth and paracrine arrest activities.
dWidth of zone of growth arrest of a lawn of CY1892 around cells of CY1455 transformed with peptide-encoding plasmid as a percentage of that observed with
CY1455 transformed with a-factor-encoding plasmid. Values are rounded to the nearest multiple of 10%.
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The autocrine activities of these agonists are reflected by
growth rates of the agonist-expressing strains in liquid media,
listed in Table 1. Paracrine measures of agonist activity—in-
duction of growth arrest of CY1892 and stimulation of histi-
dine prototrophy of CY1455—are also listed in Table 1. In the
absence of information regarding the production rates of the
various agonists, their diffusion rates in solid media, or their
permeabilities to the cell wall, these data cannot indicate the
relative potencies of the agonists. The data do, however, indi-
cate that paracrine assays of agonist activity may fail to identify
agonist peptides identified by the autocrine assay.
Compared with the selection for Ste2p agonists, genetic se-
lection for antagonists from the Mid5 library yielded a greater
number of active peptides, as was found with the Nterm li-
brary. Transformation of strain CY1892 gave about 2 3 106
Ura1 transformants, so that the likelihood that a particular
peptide would have been among the CY1892 Ura1 transfor-
mants was nearly 50%. About 2% of the transformants exhib-
ited a-factor resistance. From 28 transformants chosen for
detailed study, 21 exhibited reproducible, plasmid-dependent
a-factor resistance. All 21 plasmids isolated from these 21
transformants encode unique tridecapeptides. Twelve of the 21
plasmids failed to confer histidine prototrophy on strain
CY1455, indicating that they encode pure antagonists (Table
2). As with the analogs isolated from the Nterm library, there
are different profiles of statistically preferred amino acids
among the agonists and antagonists isolated from the Mid5
library. Specifically, although there is significant selective pres-
sure for Leu6 among both agonists and antagonists, the pref-
erence for Leu6 is greater among the agonists. More dramat-
ically, the conservation of Gly9 that is so pronounced among
agonists is not discernible among antagonists. Also, while ago-
nists exhibit a bias for either alanine or proline at position 8,
antagonists fail to show any preferences at this position. On the
other hand, both agonists and pure antagonists are similar in
that they show no preference for any amino acid or class of
amino acids at position 5 or 7.
Ste2p agonists and antagonists isolated from the Cterm
library. The Cterm library is designed to encode the a-factor
residues WHWLQLKPG at residues 1 through 9, respectively,
of the tridecapeptides, with random amino acids at positions 10
through 13. However, sequence analysis of plasmids isolated
from randomly chosen yeast transformants prior to selection
for agonist activity indicated greater diversity than intended
(see Materials and Methods). Perhaps for this reason, only one
peptide with agonist activity was isolated from 8 3 105 trans-
formants obtained with the Cterm library (Table 1), and this
peptide is [Thr7]-a-factor. Genetic selection for antagonists
yielded a greater number of active peptides. Of about 2 3 106
Ura1 transformants of strain CY1892 obtained with the Cterm
library, 84 were resistant to a-factor. Detailed study of 21 of
these yielded 13 colonies whose plasmids encode 12 different
Ste2p antagonists. Strikingly, 10 of the 12 antagonist peptides
isolated from the Cterm library exhibit some agonist activity
(Table 3), as indicated by the ability of their encoding plasmids
to confer autocrine histidine prototrophy when transformed
into strain CY1455.
Since only one agonist and two pure antagonists were iso-
lated from the Cterm library, statistical analyses of the C-
terminal residues of a-factor are limited. It is clear, however,
that each of the three classes of peptides—agonists, antago-
nists, and partial agonists—exhibits the following numerical
preferences: a proline at position 11, a nonaromatic hydropho-
bic residue at position 12; and an aromatic residue at position
13. Notably, no peptide with agonist activity contains a posi-
tively charged residue at position 10, whereas the three pure
antagonists contain arginine or lysine at this position.
Confirmation of agonist and antagonist activities from
chemically synthesized peptides. The amino acid sequences of
the bioactive peptides identified in the selections for Ste2p
TABLE 2. Genetically selected, pure antagonists of Ste2p
Library Predicted amino acid sequencea
Nterm ............................................................................................................... Cys Arg Gly Pro Gln Leu Lys Pro Gly Gln Pro Met Tyr
Cys Arg Gly Pro Gln Leu Lys Pro Gly Gln Pro Met Tyr
Cys Thr Leu Leu Gln Leu Lys Pro Gly Gln Pro Met Tyr
Leu His Leu Leu Gln Leu Lys Pro Gly Gln Pro Met Tyr
Leu His Met Leu Gln Leu Lys Pro Gly Gln Pro Met Tyr
Phe His Leu Leu Gln Leu Lys Pro Gly Gln Pro Met Tyr
Trp His Glu Leu Gln Leu Lys Pro Gly Gln Pro Met Tyr
Trp His Ser Leu Gln Leu Lys Pro Gly Gln Pro Met Tyr
Trp His Thr Leu Gln Leu Lys Pro Gly Gln Pro Met Tyr
Trp His Val Leu Gln Leu Lys Pro Gly Gln Pro Met Tyr
Mid5 ................................................................................................................. Trp His Trp Leu Ala Arg Leu Ala Leu Gln Pro Met Tyr
Trp His Trp Leu Arg Leu Trp Gly Leu Gln Pro Met Tyr
Trp His Trp Leu Asp Cys Asn Ala Gly Gln Pro Met Tyr
Trp His Trp Leu Gln Trp Arg Gln Gly Gln Pro Met Tyr
Trp His Trp Leu Gly Leu Gly Pro Ala Gln Pro Met Tyr
Trp His Trp Leu Gly Val Ala Val Gly Gln Pro Met Tyr
Trp His Trp Leu His Val Gly Ala Gly Gln Pro Met Tyr
Trp His Trp Leu Met Leu Arg Pro Gln Gln Pro Met Tyr
Trp His Trp Leu Phe Leu Thr Arg Gly Gln Pro Met Tyr
Trp His Trp Leu Ser Leu Gly Gly Arg Gln Pro Met Tyr
Trp His Trp Leu Ser Leu Gly Arg Leu Gln Pro Met Tyr
Trp His Trp Leu Val Leu Gly Asp Leu Gln Pro Met Tyr
Cterm ............................................................................................................... Trp His Trp Leu Gln Leu Lys Pro Gly Arg Pro Leu Trp
Trp His Trp Leu Gln Leu Lys Pro Gly Arg Pro Leu Trp
Trp His Trp Leu Gln Leu Lys Pro Gly Lys Pro Leu Phe
a Peptide sequences are predicted to be encoded by plasmids isolated from the Nterm, Mid5, and Cterm libraries by genetic selection for Ste2p antagonists. These
plasmids encode no agonist activity. Amino acids encoded by intentionally variable codons are shown in boldface. Each peptide is encoded by at least one unique
nucleotide sequence.
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agonists and antagonists were predicted from the nucleotide
sequence of their encoding plasmids. To assess the reliability of
these predictions, several peptides were chemically synthesized
and tested at approximately 50 to 70% purity, using growth
arrest of strain CY1892 as an assay of agonist activity and
rescue of CY1892 in the presence of a-factor as an assay of
antagonist activity (see Materials and Methods). For instance,
[Cys1,Arg2,Gly3,Pro4]-a-factor, which was encoded by two
plasmids independently isolated in the genetic screen for Ste2p
antagonists, was chemically synthesized and shown to act as a
pure antagonist. That is, while the peptide spotted on a lawn of
strain CY1892 failed to cause any discernible growth arrest
(data not shown), spotting onto an overlay of strain CY1892 on
a-factor-containing medium resulted in a zone of rescued
growth (Fig. 6). Similarly, chemically synthesized [Ser5,Asp7,
Ala8]-a-factor confirmed that this peptide, predicted to have
agonist activity, could indeed arrest growth of CY1892 (data
not shown). Thus, we conclude that the expression vector used
in these studies generally yields the expected peptide se-
quences and that the autocrine and paracrine effects of the
biologically produced peptides reflects their biochemical activ-
ities.
Additional peptides were chemically synthesized to test
structure-activity inferences made from the collection of ago-
nists and antagonists isolated from each library. For example,
Ste2p agonists genetically selected from the Nterm library ex-
hibit significant preferences for Trp1, His2, Trp3, and Leu4,
suggesting that a-factor does not readily tolerate mutation of
any of its four N-terminal residues. We tested this inference
with four chemically synthesized peptides that are point mu-
tations of a-factor (Fig. 7A). Specifically, synthetic [Ser1]-a-
factor and [Arg2]-a-factor show reduced though detectable
agonist activity, consistent with an important role for Trp1 and
His2 for a-factor activity. More dramatically, the virtual ab-
FIG. 6. Antagonist activity of chemically synthesized [Cys1,Arg2,Gly3,Pro4]-
a-factor. Peptides were spotted on an overlay of 107 cells CY1892 on solid
medium containing 50 nM a-factor. Top row, 1 ml of 10 mg of des-Trp1-[Phe3]-
a-factor per ml in dimethyl sulfoxide and serial 1:3 dilutions in water; middle row,
1 ml of 10 mg of [Cys1,Arg2,Gly3,Pro4]-a-factor per ml in dimethyl sulfoxide and
serial 1:3 dilutions in water; bottom row, 1 ml of dimethyl sulfoxide and serial 1:3
dilutions in water.
TABLE 3. Partial Ste2p antagonists
Library Predicted amino acid sequencea Autocrine agonistactivityb
Nterm Phe Asp Tyr Leu Gln Leu Lys Pro Gly Gln Pro Met Tyr 1
Phe His Met Leu Gln Leu Lys Pro Gly Gln Pro Met Tyr 1
Phe His Phe Leu Gln Leu Lys Pro Gly Gln Pro Met Tyr 11
Phe His Phe Leu Gln Leu Lys Pro Gly Gln Pro Met Tyr 11
Phe His Trp Leu Gln Leu Lys Pro Gly Gln Pro Met Tyr ND
Ser His Trp Leu Gln Leu Lys Pro Gly Gln Pro Met Tyr 111
Trp His Ala Leu Gln Leu Lys Pro Gly Gln Pro Met Tyr 1
Trp His Leu Leu Gln Leu Lys Pro Gly Gln Pro Met Tyr 111
Trp His Leu Phe Gln Leu Lys Pro Gly Gln Pro Met Tyr 1
Trp His Met Leu Gln Leu Lys Pro Gly Gln Pro Met Tyr 111
Mid5 Trp His Trp Leu Arg Arg Gly Pro Gly Gln Pro Met Tyr 11
Trp His Trp Leu Arg Leu Gln Trp Gly Gln Pro Met Tyr 111
Trp His Trp Leu Arg Leu Gly Arg Met Gln Pro Met Tyr 11
Trp His Trp Leu Arg Leu Lys Pro Gly Gln Pro Met Tyr 11
Trp His Trp Leu Gln Val Ser Val Gly Gln Pro Met Tyr 1
Trp His Trp Leu Leu Leu Thr Asp Arg Gln Pro Met Tyr 1
Trp His Trp Leu Met Leu Leu Ala Gly Gln Pro Met Tyr 111
Trp His Trp Leu Ser Thr Gly Trp Gly Gln Pro Met Tyr ND
Trp His Trp Leu Thr Leu Val Ser Gly Gln Pro Met Tyr 111
Cterm Trp His Trp Leu Gln Leu Lys Pro Gly Gln Ala Leu Phe 11
Trp His Trp Leu Gln Leu Lys Pro Gly Gln Gln Gln Trp 11
Trp His Trp Leu Gln Leu Lys Pro Gly Gln Gly Leu Trp 11
Trp His Trp Leu Gln Leu Lys Pro Gly Gln Ser Val Tyr 11
Trp His Trp Leu Gln Leu Lys Pro Gly Glu Ala Met Trp 11
Trp His Trp Leu Gln Leu Lys Pro Gly Glu Ser Leu Tyr 1
Trp His Trp Leu Gln Leu Lys Pro Gly Met Pro Leu Trp 11
Trp His Trp Leu Gln Leu Lys Pro Gly Ser Gly Leu Tyr 1
Trp His Trp Leu Gln Leu Lys Pro Gly Ser Pro Leu Trp 11
Trp His Trp Leu Gln Leu Lys Pro Gly Thr Pro Met Ser 1
a Peptide sequences are predicted to be encoded by plasmids isolated from the Nterm, Mid5, and Cterm libraries by genetic selection for Ste2p antagonists. These
plasmids encode agonist activity, as reflected by their ability to confer autocrine histidine prototrophy upon transformation of CY1455. Amino acids encoded by
intentionally variable codons are shown in boldface. Each peptide is encoded by at least one unique nucleotide sequence.
b The level of aminotriazole resistance, a measure of autocrine agonist activity, is graded in terms of the maximal aminotriazole concentration on which transformed
CY1455 can grow: 1, 0.2 mM; 11, 1 mM; 111, 5 mM. For comparison, CY1455 transformed with a-factor-encoding plasmid can grow at aminotriazole
concentrations as high as 50 mM. ND, not done.
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sence of agonist activity of synthetic [Glu3]-a-factor or [Thr4]-
a-factor is consistent with the importance of Trp3 and Leu4 of
a-factor for its activity.
Results from the Mid5 library predict that Gln5 and Lys7 are
freely mutable, Leu6 and Gly9 are critical for activity, and
alanine can substitute for Pro8. All of these predictions except
one are confirmed using synthetic peptides (Fig. 7B). As pre-
dicted, [Ala8]-a-factor shows agonist activity roughly equiva-
lent to a-factor, as does [Ser5,Asp7,Ala8]-a-factor (data not
shown). [Ser9]-a-factor shows virtually no activity, consistent
with the importance of Gly9 for a-factor activity. Similarly, the
greatly reduced activity of [Ala6]-a-factor is consistent with a
critical role for Leu6. Contrary to expectations, however,
[Arg6]-a-factor showed growth arrest activity that was equiv-
alent to a-factor. In fact, the equivalence of synthetic [Arg6]-
a-factor and a-factor was exceptional, since [Gly6]-a-factor
and [Ser6]-a-factor showed, like [Ala6]-a-factor, greatly re-
duced activity (data not shown). To examine this discrepancy
more closely, strain CY1455 was transformed with a plasmid
expressing [Arg6]-a-factor or a-factor. Cells transformed with
the a-factor-expressing construct showed far greater histidine
prototrophy than transformants expressing [Arg6]-a-factor
(data not shown). Thus, while chemically synthesized [Arg6]-
a-factor is roughly equivalent to genuine a-factor, biologically
produced [Arg6]-a-factor has relatively little autocrine activity.
This anomaly is discussed below.
The genetic selections of the Cterm library indicate that
wild-type residues Gln10 and Pro11 are important for a-factor
activity. The reduced activity of synthetic [Asn10]-a-factor and
undetectable activity of [Val11]-a-factor (Fig. 7C) are consis-
tent with a requirement for Gln10 and Pro11. Genetic selec-
tions also indicate that leucine and tryptophan can substitute
for Met12 and Tyr13, respectively. Indeed, synthetic [Leu12]-
a-factor and [Trp13]-a-factor are potent Ste2p agonists (Fig.
7C).
Residues other than wild type were more heavily repre-
sented at three positions among the genetically selected pep-
tides. That is, alanine, leucine, and tryptophan appeared more
frequently than the wild-type proline, methionine, and tyrosine
at positions 8, 12, and 13, respectively. Although none of these
substitutions, by itself, shows greater agonist activity than gen-
uine a-factor, it is possible that a peptide with all three may
show greater activity than a-factor. But chemically synthesized
[Ala8,Leu12,Trp13]-a-factor actually shows a smaller zone of
growth arrest than either a-factor or any of the single substi-
tutions (Fig. 7D).
DISCUSSION
We find that Ste2p agonists and antagonists share prefer-
ences for histidine, leucine, leucine, proline, a nonaromatic
hydrophobic residue, and an aromatic residue at positions 2, 4,
6, 11, 12, and 13, respectively. Agonists show additional pref-
erences for residues tryptophan, tryptophan, proline or ala-
nine, and glycine at positions 1, 3, 8, and 9, respectively (Table
4). We suggest that the preferred residues that are unique to
the agonists contribute to receptor activation, while those con-
served among both agonists and antagonists participate in
Ste2p binding. In the absence of measurements of binding
affinity or agonist efficacy, such functional assignments are
speculative. Nonetheless, they allow us to hypothesize princi-
pal functions for each residue of a-factor that can be tested in
future studies (Table 4).
Limitations of the autocrine selection and data analysis.We
anticipated that not every peptide sequence that could function
as an agonist or antagonist would score positive in the auto-
FIG. 7. Agonist activities of chemically synthesized a-factor analogs. Pep-
tides (0.5 mg) were spotted on lawns of 107 cells CY1892. (A) [Ser1]-a-factor
(S1), [Arg2]-a-factor (R2), [Glu3]-a-factor (E3), [Thr4]-a-factor (T4), and a-fac-
tor (a-f). (B) [Ala6]-a-factor (A6), [Arg6]-a-factor (R6), [Ala8]-a-factor (A8),
[Ser9]-a-factor (S9), and a-factor. (C) [Asn10]-a-factor (N10), [Val11]-a-factor
(V11), [Leu12]-a-factor (L12), [Trp13]-a-factor (W13), and a-factor. (D) [Ala8]-
a-factor (A8), [Ala8,Leu12,Trp13]-a-factor (A8,L12W13), [Leu12]-a-factor
(L12), [Trp13]-a-factor (W13), and a-factor.
TABLE 4. Interpretations of results and hypotheses of roles of a-factor amino acids
Position
Functionally important residuea Hypothesized role of
a-factor residuebSelected agonist Selected antagonist a-Factor
1 W W Agonist efficacy
2 H H H Binding affinity
3 W W Agonist efficacy
4 L L L Binding affinity
5 Q ?
6 L L L Binding affinity
7 K Cleavage by BAR1 protease
8 A or P P Agonist efficacy (structural)
9 G G Agonist efficacy (structural)
10 Q Q Agonist efficacy (structural)
11 P P P Binding affinity
12 Nonaromatic hydrophobic Nonaromatic hydrophobic M Binding affinity
13 Aromatic Aromatic Y Binding affinity
a On the basis of results of this study, including genetically selected and chemically synthesized Ste2p agonists and antagonists, we list residues that are preferred
among agonists and antagonists. Also listed is the sequence of a-factor, each of whose residues is presumably important for some aspect of a-factor biology.
b On the basis of results of this and previous studies (9–14, 18–20, 22, 23, 30), we hypothesize the principal contribution of each amino acid of a-factor to its biology.
These hypotheses are speculative and invite experimental testing, bearing in mind that individual residues may serve multiple functions.
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crine selection procedure and, reciprocally, that not every
tridecapeptide chemically synthesized from the predicted se-
quence of a positive clone obtained from the selection proce-
dure would have the predicted biological activity. One reason
for the lack of complete correspondence could be inappropri-
ate processing of the prepropeptide. The expression vector
that we have used is designed to direct the synthesis of a
primary translation product containing the MFa prepro se-
quences appended to the N terminus of the mature peptide.
Correct processing of this precursor protein requires endopro-
teolytic cleavage after the Lys and Arg at residues 84 and 85 of
the precursor by Kex2p, followed by removal of two tandem
Glu-Ala dipeptides by Ste13p to yield the N terminus of the
mature peptide (for a review, see reference 26). At some fre-
quency, Kex2p will cleave within the peptide sequence. Such
proteolytic activity may account for the dramatic difference in
activities of chemically synthesized and plasmid-encoded
[Arg6]-a-factor. That is, substitution of Leu6 with arginine will
generate an internal Arg-Lys dipeptide, which may be recog-
nized by Kex2p (7). Also, Ste13p may not always generate the
predicted N terminus of the secreted peptide. Although the
activity of Ste13p is relatively insensitive to residues following
N-terminal Glu-Ala dipeptides (4, 5), some of the peptides
encoded by the plasmid libraries may influence Ste13p activity.
Other conceivable complications can occur with expression of
peptides that fortuitously contain glycosylation signals, stop-
transfer signals, etc. In such cases, the active species may not
be the peptide that is predicted to be secreted. In general, this
can be addressed by testing the effects of exogenously added,
chemically synthesized peptides, bearing in mind such con-
founding issues as permeability of the cell wall to the peptides.
We have interpreted the conservation of particular residues
among both agonists and antagonists in terms of direct inter-
action with the presumed target, Ste2p. However, a conserved
residue may be required not for interaction with Ste2p per se
but rather for peptide presentation to the receptor. Leu6, for
example, may satisfy a constraint in transport or maturation of
the peptide (constraints that may not be met by arginine, for
example) and may be unimportant for receptor binding. This
could explain the substantial bias for Leu6 among agonists and
antagonists identified in the genetic screen, despite the nearly
wild-type activity of synthetic [Arg6]-a-factor.
We have used peptides chemically synthesized to 50 to 70%
purity to test certain results of the autocrine selection proce-
dure. It seems unlikely that similar unintended analogs would
be generated during chemical and biological synthesis of a
particular peptide. For this reason, results obtained with chem-
ically made peptides are most reliable when they corroborate
results obtained with in vivo selection. When the results differ,
however, the impurity of the chemically synthesized peptide
precludes clear interpretation of the results. For example, the
apparently wild-type biological activity of chemically but not
biologically synthesized [Arg6]-a-factor may be due to a potent
analog contaminating the synthesized [Arg6]-a-factor.
Lastly, our analysis treats each position of the tridecapep-
tides independently of the 12 others, ignoring possible inter-
actions among positions. In fact, the functions of residues are
likely interdependent, admitting the possibility that combina-
tions of mutations may be permitted in agonists while the
single mutations are inactive. Our data set is too small to test
for such interdependence. With a sufficiently large data set,
however, nonrandom coincidence of particular residues at par-
ticular positions could be detected, perhaps allowing identifi-
cation of determinants defined by multiple residues.
Structure-activity inferences from autocrine selection of
agonists and antagonists. (i) The amino-terminal domain. The
results obtained in this study generally confirm a model of
a-factor in which the N-terminal region contains major deter-
minants of agonist activity. In particular, the dramatic conser-
vation of Trp1 and Trp3 among agonists but not pure antag-
onists argues strongly for their importance in activating Ste2p,
consistent with the inactivity of chemically synthesized [Ser1]-
a-factor and [Glu3]-a-factor. On the other hand, conservation
of His2 and Leu4 among both agonists and antagonists indi-
cates that these residues are important for both activities. In
the case of Leu4, the findings are consistent with the virtual
absence of activity of chemically synthesized [Thr4]-a-factor.
In the case of His2, the findings are consistent with the low
activity of synthetic [Arg2]-a-factor and with previous studies
(3, 19). It is noteworthy that a truncated analog of a-factor that
lacks both Trp1 and His2 exhibits about 25% the binding
affinity but less than 0.1% the bioactivity of a-factor (10, 22).
Our results indicating an important role for His2 for both
agonist and antagonist activities may indicate that His2 of
a-factor contributes to a spatial positioning of Trp1 that per-
mits interaction with the receptor.
Despite the preference for N-terminal a-factor residues at
particular positions among the agonist and antagonist analogs,
we recovered both an agonist and an antagonist that differ
from a-factor at all of the four N-terminal residues. We chem-
ically synthesized the predicted antagonist, [Cys1,Arg2,Gly3,
Pro4]-a-factor, and confirmed it to be an antagonist. Judging
from its ability to rescue a larger zone of growth of a-factor-
arrested CY1892, [Cys1,Arg2,Gly3,Pro4]-a-factor showed
greater antagonist activity than the known inhibitor des-Trp1-
[Phe3]-a-factor (22). These peptides indicate that there are
multiple solutions to the problems of binding to and, in the
case of the agonist, activating Ste2p and that these solutions
may be achieved with novel, unanticipated peptides. Notably,
both the agonist and the antagonist contain a single cysteine
residue, which admits the possibility that the bioactive species
is a dimer in both cases.
(ii) The central domain.While previous studies have shown
that substitution of Leu6 with D-leucine is accompanied by loss
of a-factor activity (19), the conservation of Leu6 among all
selected peptides indicates its importance for both agonism
and antagonism. Pro8 and Gly9, on the other hand, show
significant conservation only among agonists, suggesting that
they make specific contributions to agonist activity.
Naider and colleagues have obtained substantial evidence
that a-factor can form a transient type II b turn centered at
Pro8-Gly9 and that this conformation may be important for its
activity (11, 12, 30). In view of these findings, the ability of
alanine to substitute for proline, suggested by the results of the
genetic screen and confirmed with synthetic peptides, implies
that alanine may participate in forming a structure that func-
tionally resembles the b turn formed by Pro8-Gly9. Clearly, the
apparent functional equivalence of proline and alanine at po-
sition 8 is independent of the proposal that a-factor assumes a
b turn. Rather, any model that describes the activity of a-factor
must account for this equivalence.
Conservative substitutions at positions 5 and 7 have previ-
ously been shown to have no effect on the agonist activity of
a-factor (22). Our results demonstrate that even coincident,
nonconservative substitutions at these positions are tolerated.
Thus, [Ser5,Ser7]-a-factor, [Ser5,Val7]-a-factor, [Ser5,Tyr7]-
a-factor, [Arg5,Gln7]-a-factor, [Leu5,Gln7]-a-factor, and
[Tyr5,Arg7]-a-factor were all identified in the genetic selection
as Ste2p agonists. There are, however, limits to the silent
substitutions that can occur for Lys7 of a-factor, since its re-
placement with D-lysine is reported to result in dramatic loss of
agonist activity (19). Of course, the relative dispensability of
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Gln5 and Lys7 of a-factor is valid only in the narrow context of
our selection for Ste2p agonists; these residues may contribute
to other biological aspects of a-factor that are not targeted by
our selections. For example, a-factor is normally proteolyzed
by the BAR1 protease, which cleaves between Leu6 and Lys7
(9, 23), thereby enabling desensitization of wild-type a cells.
Thus, one can envision other selection schemes that might
demonstrate an important role for Lys7 in the lability of a-fac-
tor.
(iii) The carboxyl domain. Three aspects of our results are
consistent with an important role for C-terminal residues in
a-factor activity. First, we find that aromatic residues, espe-
cially tryptophan, are heavily overrepresented at position 13
among all selected peptides. The apparent ability of trypto-
phan to substitute for Tyr13 of a-factor was confirmed by using
synthetic [Trp13]-a-factor, which showed agonist activity
roughly equivalent to that of a-factor. Second, it has been
shown previously that [Nle12]-a-factor, in which Met12 is re-
placed with the isosteric norleucine, shows nearly wild-type
affinity and bioactivity (22). We find that the bioactivity of
synthetic [Leu12]-a-factor is roughly equivalent to that of gen-
uine a-factor, suggesting that certain nonsteric substitutions of
Met12 are also tolerated. Such nonsteric substitutions must
preserve the nonaromatic hydrophobic character of the Met12
side chain. Finally, our results with both genetically selected
and chemically synthesized peptides argue that both Gln10 and
Pro11 are important for a-factor activity.
Autocrine genetic selection as a discovery tool. We have
developed an autocrine system that permits genetic selection
of Ste2p agonists and antagonists. We have used this system to
determine structure-activity relationships for a-factor and, in
so doing, have demonstrated its utility for discovering novel
activators and inhibitors of Ste2p. Indeed, using a completely
random library encoding tridecapeptides, we have recently
identified Ste2p ligands that bear no resemblance to a-factor at
the primary sequence level. In view of the ability to express
mammalian G-protein-coupled receptors in yeast strains (15,
21), this selection system can therefore be used to discover
novel peptide agonists and antagonists of known mammalian
receptors. The system may also be used to develop surrogate
ligands for G-protein-coupled receptors whose physiologic li-
gands have yet to be identified.
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